Cochrane · systematic review · CD013595
Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant
Langer, P, John, L, Monsef, I, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Daratumumab plus standard therapy compared to standard therapy for people with newly diagnosed multiple myeloma ineligible for transplant
Population: people with newly diagnosed multiple myeloma ineligible for transplant
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (at 36 months) Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | HR 0.64 [0.53, 0.76] | 2 studies · 1443 participants | Moderate Downgraded: risk of bias |
Progression‐free survival (at 24 months) Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | HR 0.48 [0.39, 0.58] | 3 studies · 1663 participants | Moderate Downgraded: risk of bias |
Quality of life: EORTC 12 monthScale from: 0 to 100 Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | no estimate extracted | 3 studies · 1096 participants | Low Downgraded: risk of bias, imprecision |
On‐study mortality (longest available Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | Risk Ratio 0.72 [0.62, 0.83] | 3 studies · 1644 participants | Moderate Downgraded: risk of bias |
Serious adverse events (longest available Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | Risk Ratio 1.18 [1.02, 1.37] | 3 studies · 1644 participants | Moderate Downgraded: risk of bias |
Adverse events (CTCAE grade ≥ 3) (longest available Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | Risk Ratio 1.01 [0.99, 1.02] | 3 studies · 1644 participants | Moderate Downgraded: risk of bias |
Adverse events: infections (CTCAE grade ≥ 3) (longest available Summary of findings table ‐ Daratumumab plus standard therapy vs standard therapy | Risk Ratio 1.52 [1.3, 1.78] | 3 studies · 1644 participants | Moderate Downgraded: risk of bias |